The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The unaudited consolidated financial statements of Brooks Automation, Inc. and its subsidiaries (“Brooks”, or the “Company”) included herein have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP").
The accompanying Consolidated Balance Sheet as of September 30, 2017 was derived from the audited annual consolidated financial statements as of the period then ended.
Net foreign currency transaction and remeasurement losses totaled $0.6 million and $0.7 million, respectively, during the three months ended June 30, 2018 and 2017, and $3.1 million and $1.6 million, respectively, during the nine months ended June 30, 2018 and 2017.
The Company expects to adopt the guidance during the first quarter of fiscal year 2020 and is evaluating the effect that ASU 2018-02 will have on its consolidated financial statements and related disclosures.
Entities should determine at the inception of the arrangement whether a contract represents a lease or contains a lease which is defined as a right to control the use of identified property for a period of time in exchange for consideration.
Entities are required to estimate expected credit losses over the life of financial assets and record an allowance against the assets’ amortized cost basis to present the assets at the amount expected to be collected.This section provides an analysis of our financial results for the three and nine months ended June 30, 2018 compared to the three and nine months ended June 30, 2017.
This Quarterly Report on Form 10‑Q contains statements that are, or may be considered to be, forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Our leadership position and global support structure in each of these markets makes us a valued business partner to some of the world’s largest semiconductor capital equipment and device makers as well as pharmaceutical and life science companies and research institutions in the world.
In October 2017, we acquired all of the outstanding capital stock of 4titude Limited, or 4titude, a U.K.-based manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications, for a total purchase price of $65.1 million, net of cash acquired.
Results of Operations- Revenue for the three months ended June 30, 2018 increased to $223.5 million, or by 23%, as compared to the corresponding period of the prior fiscal year.
Gross margin was 39.9% for the third quarter of fiscal year 2018 as compared to 39.4% for the third quarter of fiscal year 2017, which resulted in an increase in gross profit of $17.7 million.
Operating expenses were $62.5 million during the third quarter of fiscal year 2018 as compared to $52.8 million during the third quarter of fiscal year 2017, an increase of $9.7 million.
Net income was $22.6 million for the three months ended June 30, 2018 as compared to $17.4 million for the corresponding period of the prior fiscal year.